Interactions of dietary phytochemicals with ABC transporters: Possible implications for drug disposition and multidrug resistance in cancer

Drug Metabolism Reviews

Volumn 42, Issue 4, 2010, Pages 590-611

  Li, Yan ^a   Revalde, Jezrael L ^a   Reid, Glen ^a,b   Paxton, James W ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

ABC transporter; Cancer; Multidrug resistance; Pharmacokinetics; Phytochemical

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; APIGENIN; BIOCHANIN A; CATECHIN; CURCUMIN; CYANIDIN 3 GLUCOSIDE; DAIDZEIN; ELACRIDAR; EPICATECHIN; EPIGALLOCATECHIN; FLAVANOL DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOID; FLAVONOL DERIVATIVE; GALLOCATECHIN; GENISTEIN; ISOFLAVONE DERIVATIVE; LUTEOLIN; MALVIDIN CHLORIDE; MYRICETIN; NARINGENIN; PELARGONIDIN; PLANT MEDICINAL PRODUCT; PROANTHOCYANIDIN DERIVATIVE; PUERARIN; QUERCETIN; RESVERATROL; SILYMARIN; TARIQUIDAR; UNINDEXED DRUG; XENOBIOTIC AGENT; ZOSUQUIDAR;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; DRUG DISPOSITION; DRUG EXCRETION; DRUG MECHANISM; FOOD DRUG INTERACTION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; HUMANS; NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS; PROTEIN BINDING;

EID: 77957594068     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602531003758690     Document Type: Review

References (262)

1. Allen, J. D., Brinkhuis, R. F., Wijnholds, J., Schinkel, A. H. (1999). The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59:4237-4241.
2. Allen, J. D., van Loevezijn, A., Lakhai, J. M., van der Valk, M., van Tellingen, O., Reid, G., et al. (2002). Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitre- morgin C. Mol Cancer Ther 1:417-425.
3. Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., et al. (2009). Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718-1722.
4. Anand, P., Thomas, S. G., Kunnumakkara, A. B., Sundaram, C., Harikumar, K. B., Sung, B., et al. (2008). Biological activities of curcumin and its analogues (Congeners) made by man and mother nature. Biochem Pharmacol 76:1590-1611.
5. Ando, T., Kusuhara, H., Merino, G., Alvarez, A. I., Schinkel, A. H., Sugiyama, Y. (2007). Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos 35:1873-1879.
6. Anuchapreeda, S., Leechanachai, P., Smith, M. M., Ambudkar, S. V., Limtrakul, P. N. (2002). Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64:573-582.
7. Arora, A., Seth, K., Kalra, N., Shukla, Y. (2005). Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol. Toxicol Appl Pharmacol 202: 237-243.
8. Arora, A., Seth, K., Shukla, Y. (2004). Reversal of P-glycoprotein- mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver. Carcinogenesis 25:941-949.
9. Arora, A., Shukla, Y. (2003). Modulation of vinca-alkaloid induced P-glycoprotein expression by indole-3-carbinol. Cancer Lett 189:167-173.
10. Aruoma, O. I., Bahorun, T., Jen, L-S. (2003). Neuroprotection by bioac- tive components in medicinal and food plant extracts. Mutat Res Rev Mutat Res 544:203-215.
11. Balunas, M. J., Kinghorn, A. D. (2005). Drug discovery from medicinal plants. Life Sci 78:431-441.
12. Banerjee, S., Wang, Z., Kong, D., Sarkar, F. H. (2009). 3,3'-diindolyl- methane enhances chemosensitivity of multiple chemothera- peutic agents in pancreatic cancer. Cancer Res 69:5592-5600.
13. Banerjee, S., Zhang, Y., Ali, S., Bhuiyan, M., Wang, Z., Chiao, P. J., et al. (2005). Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65:9064-9072.
14. Baur, J. A., Sinclair, D. A. (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493-506.
15. Belhoussine, R., Morjani, H., Lahlil, R., Manfait, M. (1997). Evidence for reversal of multidrug resistance by quinine in LR73 cells without alteration of nuclear pirarubicin uptake and downregulation of mdr1 gene expression. Int J Cancer 73:600-606.
16. Belinsky, M. G., Guo, P., Lee, K., Zhou, F., Kotova, E., Grinberg, A., et al. (2007). Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue- induced damage. Cancer Res 67:262-268.
17. Benet, L. Z. (2009). The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm 6:1631-1643.
18. Bera, T. K., Lee, S., Salvatore, G., Lee, B., Pastan, I. (2001). MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol Med 7:509-516.
19. Bhardwaj, R. K., Glaeser, H., Becquemont, L., Klotz, U., Gupta, S. K., Fromm, M. F. (2002). Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther302:645-650.
20. Bisht, S., Feldmann, G., Soni, S., Ravi, R., Karikar, C., Maitra, A. (2007). Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnol 5:3.
21. Boraldi, F., Quaglino, D., Croce, M. A., Garcia Fernandez, M. I., Tiozzo, R., Gheduzzi, D., et al. (2003). Multidrug resistance protein-6 (MRP6) in human dermal fibroblasts. Comparison between cells from normal subjects and from Pseudoxanthoma elasticum patients. Matrix Biol 22:491-500.
22. Borst, P., Elferink, R. O. (2002). Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592.
23. Borst, P., Evers, R., Kool, M., Wijnholds, J. (1999). The multidrug resistance protein family. Biochim Biophys Acta 1461:347-357.
24. Borst, P., Evers, R., Kool, M., Wijnholds, J. (2000). A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302.
25. Boumendjel, A., Di Pietro, A., Dumontet, C., Barron, D. (2002). Recent advances in the discovery of flavonoids and analogs with high- affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev 22:512-529.
26. Breedveld, P., Pluim, D., Cipriani, G., Dahlhaus, F., van Eijndhoven, M. A., de Wolf, C. J., et al. (2007). The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol 71:240-249.
27. Breedveld, P., Pluim, D., Cipriani, G., Wielinga, P., van Tellingen, O., Schinkel, A. H., et al. (2005). The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imat- inib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582.
28. Callaway, E. C., Zhang, Y., Chew, W., Chow, H. H. (2004). Cellular accumulation of dietary anticarcinogenic isothiocyanates is followed by transporter-mediated export as dithiocarbamates. Cancer Lett 204:23-31.
29. Castro, A. F., Altenberg, G. A. (1997). Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem Pharmacol 53:89-93.
30. Cavet, M. E., West, M., Simmons, N. L. (1996). Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 118:1389-1396.
31. Chearwae, W., Shukla, S., Limtrakul, P., Ambudkar, S. V. (2006). Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemo- preventive agent curcumin. Mol Cancer Ther 5:1995-2006.
32. Chen, C., Johnston, T. D., Jeon, H., Gedaly, R., McHugh, P. P., Burke, T. G., et al. (2009). An in vitro study of liposomal curcumin: stability, toxicity, and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells. Int J Pharm 366:133-139.
33. Chen, C., Kong, A. N. (2005). Dietary cancer-chemopreventive compounds: from signaling and gene expression to pharmacological effects. Trends Pharmacol Sci 26:318-326.
34. Chen, G., Duran, G. E., Steger, K. A., Lacayo, N. J., Jaffrezou, J. P., Dumontet, C., et al. (1997). Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J Bio Chem 272:5974-5982.
35. Chen, Z-S., Furukawa, T., Sumizawa, T., Ono, K., Ueda, K., Seto, K., et al. (1999). ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK- 104P. Mol Pharmacol 55:921-928.
36. Chen, Z. S., Lee, K., Kruh, G. D. (2001). Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Bio Chem 276:33747-33754.
37. Cherrington, N. J., Hartley, D. P., Li, N., Johnson, D. R., Klaassen, C. D. (2002). Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 300:97-104.
38. Choi, B. H., Kim, C. G., Lim, Y., Shin, S. Y., Lee, Y. H. (2008). Curcumin downregulates the multidrug-resistance mdrib gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett 259:111-118.
39. Choi, J. S., Choi, H. K., Shin, S. C. (2004a). Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int J Pharm 275:165-170.
40. Choi, J. S., Jo, B. W., Kim, Y. C. (2004b). Enhanced paclitaxel bio- availability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm 57: 313-318.
41. Choi, J. S., Shin, S. C. (2005). Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. Int J Pharm 292:149-156.
42. Choi, S. U., Park, S. H., Kim, K. H., Choi, E. J., Kim, S., Park, W. K., et al. (1998). The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance- related drugs via modulation of P-glycoprotein. Anticancer Drugs 9:255-261.
43. Christensen, J., LeBlanc, G. (1996). Reversal of multidrug resistance in vivo by dietary administration of the phytochemical indole-3 -carbinol. Cancer Res 56:574-581.
44. Chu, X. Y., Huskey, S. E., Braun, M. P., Sarkadi, B., Evans, D. C., Evers, R. (2004). Transport of ethinylestradiol glucuronide and ethi- nylestradiol sulfate by the multidrug-resistance proteins MRP1, MRP2, and MRP3. J Pharmacol Exp Ther 309:156-164.
45. Cisternino, S., Mercier, C., Bourasset, F., Roux, F., Scherrmann, J. M. (2004). Expression, upregulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64:3296-3301.
46. Clark, R., Kerr, I. D., Callaghan, R. (2006). Multiple drug-binding sites on the R482G isoform of the ABCG2 transporter. Br J Pharmacol 149:506-515.
47. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654.
48. Collett, A., Higgs, N. B., Sims, E., Rowland, M., Warhurst, G. (1999). Modulation of the permeability of H2 receptor antagonists, cimetidine and ranitidine, by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J Pharmacol Exp Ther 288:171-178.
49. Conseil, G., Baubichon-Cortay, H., Dayan, G., Jault, J. M., Barron, D., Di Pietro, A. (1998). Flavonoids: a class of modulators with bifunc- tional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci U S A 95:9831-9836.
50. Cooray, H. C., Janvilisri, T., van Veen, H. W., Hladky, S. B., Barrand, M. A. (2004). Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun 317:269-275.
51. Corea, G., Fattorusso, E., Lanzotti, V., Taglialatela-Scafati, O., Appendino, G., Ballero, M., et al. (2003). Jatrophane diterpenes as P-glycoprotein inhibitors. First insights of structure-activity relationships and discovery of a new, powerful lead. J Med Chem 46:3395-3402.
52. Critchfield, J. W., Welsh, C. J., Phang, J. M., Yeh, G. C. (1994). Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol 48:1437-1445.
53. Cui, J., Yu, B., Zhao, Y., Zhu, W., Li, H., Lou, H., et al. (2009). Enhancement of oral absorption of curcumin by self-microemul- sifying drug delivery systems. Int J Pharm 371:148-155.
54. Dauchy, S., Miller, F., Couraud, P. O., Weaver, R. J., Weksler, B., Romero, I. A., et al. (2009). Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol 77:897-909.
55. Dayan, G., Baubichon-Cortay, H., Jault, J. M., Cortay, J. C., Deleage, G., Di Pietro, A. (1996). Recombinant N-terminal nucleotide-binding domain from mouse P-glycoprotein. Overexpression, purification, and role of cysteine 430. J Biol Chem 271:11652-11658.
56. de Bruin, M., Miyake, K., Litman, T., Robey, R., Bates, S. E. (1999). Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 146:117-126.
57. De Castro, W. V., Mertens-Talcott, S., Derendorf, H., Butterweck, V. (2007). Grapefruit juice-drug interactions: grapefruit juice and its components inhibit p-glycoprotein (ABCB1)-mediated transport of talinolol in Caco-2 cells. J Pharm Sci 96:2808-2817.
58. de Wolf, C., Jansen, R., Yamaguchi, H., de Haas, M., van de Wetering, K., Wijnholds, J., et al. (2008). Contribution of the drug transporter, ABCG2 (breast cancer resistance protein), to resistance against anticancer nucleosides. Mol Cancer Ther 7:3092-3102.
59. Deli, J., Molnar, P., Matus, Z., Toth, G. (2001). Carotenoid composition in the fruits of red paprika (Capsicum annuum var. lycopersiciforme rubrum) during ripening; biosynthesis of caro- tenoids in red paprika. J Agric Food Chem 49:1517-1523.
60. Dembinska-Kiec, A., Mykkanen, O., Kiec-Wilk, B., Mykkanen, H. (2008). Antioxidant phytochemicals against type 2 diabetes. Br J Nutr 99(E Suppl 1):ES109-E117.
61. Demeule, M., Brossard, M., Turcotte, S., Regina, A., Jodoin, J., Beliveau, R. (2004). Diallyl disulfide, a chemopreventive agent in garlic, induces multidrug-resistance-associated protein 2 expression. Biochem Biophys Res Commun 324:937-945.
62. Dhillon, N., Aggarwal, B. B., Newman, R. A., Wolff, R. A., Kunnumakkara, A. B., Abbruzzese, J. L., et al. (2008). Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14:4491-4499.
63. Doerge, D. R., Churchwell, M. I., Chang, H. C., Newbold, R. R., Delclos, K. B. (2001). Placental transfer of the soy isoflavone, genistein, following dietary and gavage administration to Sprague-Dawley rats. Reprod Toxicol 15:105-110.
64. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., et al. (1998) A multidrug-resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95:15665-15670.
65. Drach, J., Gsur, A., Hamilton, G., Zhao, S., Angerler, J., Fiegl, M., et al. (1996). Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 88:1747-1754.
66. Dreiseitel, A., Oosterhuis, B., Vukman, K. V., Schreier, P., Oehme, A., Locher, S., et al. (2009). Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1. Br J Pharmacol 158:1942-1950.
67. Dresser, G. K., Schwarz, U. I., Wilkinson, G. R., Kim, R. B. (2003). Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 73: 41-50.
68. Dudeja, P., Anderson, K., Harris, J., Buckingham, L., Coon, J. (1995). Reversal of multidrug-resistance phenotype by surfactants: relationship to membrane-lipid fluidity. Arch Biochem Biophys 319:309-315.
69. Durr, D., Stieger, B., Kullak-Ublick, G. A., Rentsch, K. M., Steinert, H. C., Meier, P. J. (2000). St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598-604.
70. Duthie, S. J. (2007). Berry phytochemicals, genomic stability, and cancer: evidence for chemoprotection at several stages in the carcinogenic process. Mol Nutr Food Res 51:665-674.
71. Ebert, B., Seidel, A., Lampen, A. (2005). Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 26:1754-1763.
72. Ebert, B., Seidel, A., Lampen, A. (2007). Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicol Sci 96:227-236.
73. Enokizono, J., Kusuhara, H., Sugiyama, Y. (2007). Effect of breast cancer resistance protein (bcrp/abcg2) on the disposition of phytoestrogens. Mol Pharmacol 72:967-975. (Pubitemid 47481419)
74. Espin, J. C., Garcia-Conesa, M. T., Tomas-Barberan, F. A. (2007). Nutraceuticals: facts and fiction. Phytochemistry 68:2986-3008.
75. Evseenko, D. A., Paxton, J. W., Keelan, J. A. (2006). ABC drug- transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. Am J Physiol Regul Integr Comp Physiol 290:R1357-R1365.
76. Faber, K. N., Muller, M., Jansen, P. L. (2003). Drug transport proteins in the liver. Adv Drug Deliv Rev 55:107-124.
77. Fetsch, P. A., Abati, A., Litman, T., Morisaki, K., Honjo, Y., Mittal, K., et al. (2006). Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett 235: 84-92.
78. Fletcher, J. I., Haber, M., Henderson, M. J., Norris, M. D. (2010). ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10:147-156.
79. Fong, W. F., Wan, C. K., Zhu, G. Y., Chattopadhyay, A., Dey, S., Zhao, Z., et al. (2007). Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp- substrate complexes. Planta Med 73:212-220.
80. Fox, E., Bates, S. E. (2007). Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Exp Rev Anticancer Ther 7: 447-459.
81. Fricker, G., Gutmann, H., Droulle, A., Drewe, J., Miller, D. (1999). Epithelial transport of anthelmintic ivermectin in a novel model of isolated proximal kidney tubules. Pharm Res 16: 1570-1575.
82. Friedman, L., Lin, L., Ball, S., Bekaii-Saab, T., Fuchs, J., Li, P. K., et al. (2009) Curcumin analogues exhibit enhanced growth suppres- sive activity in human pancreatic cancer cells. Anticancer Drugs 20:444-449.
83. Fu, L., Liang, Y., Deng, L., Ding, Y., Chen, L., Ye, Y., et al. (2004). Characterization of tetrandrine, a potent inhibitor of P- glycoprotein-mediated multidrug resistance. Cancer Chemother Pharmacol 53:349-356.
84. Gan, L. S., Moseley, M. A., Khosla, B., Augustijns, P. F., Bradshaw, T. P., Hendren, R. W., et al. (1996). CYP3A-like cytochrome P450- mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos 24:344-349.
85. Hall, M. D., Handley, M. D., Gottesman, M. M. (2009). Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 30:546-556.
86. Han, Y., Chin, Tan, T. M., Lim, L. Y. (2008). In vitro and in vivo evaluation of the effects of piperine on P-gp function and expression. Toxicol Appl Pharmacol 230:283-289.
87. Harris, K. E., Jeffery, E. H. (2008). Sulforaphane and erucin increase MRP1 and MRP2 in human carcinoma cell lines. J Nutr Biochem 19:246-254.
88. Hatcher, H., Planalp, R., Cho, J., Torti, F. M., Torti, S. V. (2008). Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65:1631-1652.
89. Higgins, C. F. (1992). ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8:67-113.
90. Hilgendorf, C., Ahlin, G., Seithel, A., Artursson, P., Ungell, A. L., Karlsson, J. (2007). Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35:1333-1340.
91. Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H., Sugiyama, Y. (2005). Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:800-807.
92. Hong, J., Lambert, J. D., Lee, S. H., Sinko, P. J., Yang, C. S. (2003). Involvement of multidrug-resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun 310:222-227.
93. Hooivelda, G. J. E. J., van Montfoorta, J. E. (2000). Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport. Eur J Pharm Sci 12:13-30.
94. Hooper, L., Kroon, P. A., Rimm, E. B., Cohn, J. S., Harvey, I., Le Cornu, K. A., et al. (2008). Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized, controlled trials. Am J Clin Nutr 88:38-50.
95. Hou, X. L., Takahashi, K., Tanaka, K., Tougou, K., Qiu, F., Komatsu, K., et al. (2008). Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite ways. Int J Pharm 358:224-229.
96. Houghton, P. J., Germain, G. S., Harwood, F. C., Schuetz, J. D., Stewart, C. F., Buchdunger, E., et al. (2004). Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64: 2333-2337.
97. Hsiao, P., Bui, T., Ho, R. J., Unadkat, J. D. (2008). In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier. Drug Metab Dispos 36:481-484.
98. Huisman, M. T., Smit, J. W., Crommentuyn, K. M., Zelcer, N., Wiltshire, H. R., Beijnen, J. H., et al. (2002). Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16:2295-2301.
99. Huls, M., Brown, C. D., Windass, A. S., Sayer, R., van den Heuvel, J. J., Heemskerk, S., et al. (2008). The breast cancer resistance protein transporter, ABCG2, is expressed in the human kidney proximal tubule apical membrane. Kidney Int 73:220-225.
100. Huls, M., Russel, F. G., Masereeuw, R. (2009). The role of ATP-binding cassette transporters in tissue defense and organ regeneration. J Pharmacol Exp Ther 328:3-9.
101. Ichikawa, M., Yoshimura, A., Sumizawa, T., Shudo, N., Kuwazuru, Y., Furukawa, T., et al. (1991). Interaction of organic chemicals with P-glycoprotein in the adrenal gland, kidney, and a multidrug- resistant KB cell. J Bio Chem 266:903-908.
102. Imai, Y., Asada, S., Tsukahara, S., Ishikawa, E., Tsuruo, T., Sugimoto, Y. (2003). Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 64:610-618.
103. Imai, Y., Tsukahara, S., Asada, S., Sugimoto, Y. (2004). Phytoestrogens/ flavonoids reverse breast cancer resistance protein/ABCG2- mediated multidrug resistance. Cancer Res 64:4346-4352.
104. Jan, T., Hans, T., Greger, L., Curt, E. (2001). Correlation of gene expression of ten drug-efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299:164-170.
105. Jedlitschky, G., Burchell, B., Keppler, D. (2000). The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Bio Chem 275:30069-30074.
106. Ji, Y., Morris, M. E. (2005). Transport of dietary phenethyl isothio- cyanate is mediated by multidrug resistance protein 2 but not P-glycoprotein. Biochem Pharmacol 70:640-647.
107. Jin, J., Wang, F. P., Wei, H., Liu, G. (2005). Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother Pharmacol 55: 179-188. (Pubitemid 40110061)
108. Jodoin, J., Demeule, M., Beliveau, R. (2002). Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 1542:149-159.
109. Jonker, J. W., Merino, G., Musters, S., van Herwaarden, A. E., Bolscher, E., Wagenaar, E., et al. (2005). The breast cancer resistance protein, BCRP (ABCG2), concentrates drugs and carcinogenic xeno- toxins into milk. Nat Med 11:127-129.
110. Jonker, J. W., Smit, J. W. (2000). Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
111. Juan, H., Terhaag, B., Cong, Z., Bi-Kui, Z., Rong-Hua, Z., Feng, W., et al. (2007). Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers. Eur J Clin Pharmacol 63:663-668.
112. Juan, M. E., Gonzalez-Pons, E., Planas, J. M. (2010). Multidrug resistance proteins restrain the intestinal absorption of trans-resvera- trol in rats. J Nutr 140:489-495.
113. Kavallaris, M. (1997). The role of multidrug-resistance-associated protein (MRP) expression in multidrug resistance. Anticancer Drugs 8:17-25.
114. Keitel, V., Kartenbeck, J., Nies, A. T., Spring, H., Brom, M., Keppler, D. (2000). Impaired protein maturation of the conjugate export pump multidrug-resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 32:1317-1328.
115. Khan, N., Adhami, V. M., Mukhtar, H. (2008). Apoptosis by dietary agents for prevention and treatment of cancer. Biochem Pharmacol 76:1333-1339.
116. Kim, K., Park, P., Park, J. (2009). Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. Eur J Clin Pharmacol 65:609-614.
117. Kim, S. W., Kwon, H. Y., Chi, D. W., Shim, J. H., Park, J. D., Lee, Y. H., et al. (2003). Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem Pharmacol 65: 75-82.
118. Kitagawa, S., Nabekura, T., Nakamura, Y., Takahashi, T., Kashiwada, Y. (2007a). Inhibition of P-glycoprotein function by tannic acid and pentagalloylglucose. J Pharm Pharmacol 59:965-969.
119. Kitagawa, S., Takahashi, T., Nabekura, T., Tachikawa, E., Hasegawa, H. (2007b). Inhibitory effects of ginsenosides and their hydro- lyzed metabolites on daunorubicin transport in KB-C2 cells. Biol Pharm Bull 30:1979-1981.
120. Klaassen, C. D., Aleksunes, L. M. (2010). Xenobiotic, bile Acid, and cholesterol transporters: function and regulation. Pharmacol Rev 62:1-96.
121. Klopman, G., Shi, L., Ramu, A. (1997). Quantitative structure-activity relationship of multidrug-resistance reversal agents. Mol Pharmacol 52:323-334.
122. Kondo, C., Onuki, R., Kusuhara, H., Suzuki, H., Suzuki, M., Okudaira, N., et al. (2005). Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP/ABCG2). Pharm Res 22:613-618.
123. Kool, M., Dehaas, M., Scheffer, G. L., Scheper, R. J., Vaneijk, M. J. T., Juijn, J. A., et al. (1997). Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537-3547.
124. Kool, M., van der Linden, M., de Haas, M., Baas, F. (1999). Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res 59:175-182.
125. Kris-Etherton, P. M., Hecker, K. D., Bonanome, A., Coval, S. M., Binkoski, A. E., Hilpert, K. F., et al. (2002). Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med 113:71-88.
126. Kruh, G. D., Guo, Y., Hopper-Borge, E., Belinsky, M. G., Chen, Z. S. (2007). ABCC10, ABCC11, and ABCC12. Pflugers Arch 453:675-684.
127. Kubota, H., Ishihara, H., Langmann, T., Schmitz, G., Stieger, B., Wieser, H. G., et al. (2006). Distribution and functional activity of P-glycoprotein and multidrug-resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res 68:213-228.
128. Kuhnle, G., Spencer, J. P. E., Chowrimootoo, G., Schroeter, H., Debnam, E. S., Srai, S. K. S., et al. (2000). Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun 272:212-217.
129. Kunnumakkara, A. B., Guha, S., Krishnan, S., Diagaradjane, P., Gelovani, J., Aggarwal, B. B. (2007). Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67:3853-3861.
130. Labbozzetta, M., Notarbartolo, M., Poma, P., Maurici, A., Inguglia, L., Marchetti, P., et al. (2009). Curcumin as a possible lead compound against hormone-independent, multidrug-resistant breast cancer. Ann N Y Acad Sci 1155:278-283.
131. Laberge, R. M., Karwatsky, J., Lincoln, M. C., Leimanis, M. L., Georges, E. (2007). Modulation of GSH levels in ABCC1 expressing tumor cells triggers apoptosis through oxidative stress. Biochem Pharmacol 73:1727-1737.
132. Lavie, Y., Harel-Orbital, T., Gaffield, W., Liscovitch, M. (2001). Inhibitory effect of steroidal alkaloids on drug transport and multidrug resistance in human cancer cells. Anticancer Res 21:1189-1194.
133. Lee, Y. J., Kusuhara, H., Jonker, J. W., Schinkel, A. H, Sugiyama, Y. (2005). Investigation of efflux transport of dehydroepiandroster- one sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther 312:44-52.
134. Leslie, E. M., Deeley, R. G., Cole, S. P. (2003). Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). Drug Metab Dispos 31:11-15.
135. Leslie, E. M., Deeley, R. G., Cole, S. P. (2005). Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237.
136. Li, L., Pan, Q., Sun, M., Lu, Q., Hu, X. (2007a). Dibenzocyclooctadiene lignans: a class of novel inhibitors of multidrug-resistance-asso- ciated protein 1. Life Sci 80:741-748.
137. Li, Y., Fawcett, J. P., Zhang, H., Tucker, I. G. (2007b). Transport and metabolism of MitoQ10, a mitochondria-targeted antioxidant, in Caco-2 cell monolayers. J Pharm Pharmacol 59:503-511.
138. Lim, S. L., Lim, L. Y. (2006). Effects of citrus fruit juices on cytotoxicity and drug transport pathways of Caco-2 cell monolayers. Int J Pharm 307:42-50.
139. Limtrakul, P., Chearwae, W., Shukla, S., Phisalphong, C., Ambudkar, S. V. (2007). Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2), and multidrug resistance protein 1 (ABCC1), by tet- rahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem 296:85-95.
140. Linnet, K., Ejsing, T. B. (2008). A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol 18:157-169.
141. Litman, T., Druley, T. E., Stein, W. D., Bates, S. E. (2001). From MDR to MXR: new understanding of multidrug resistance systems, their properties, and clinical significance. Cell Mol Life Sci 58:931-959.
142. Liu, B., Edgerton, S., Yang, X., Kim, A., Ordonez-Ercan, D., Mason, T., et al. (2005). Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res 65:879-886.
143. Liu, H., Yang, J., Du, F., Gao, X., Ma, X., Huang, Y., et al. (2009). Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab Dispos 37:2290-2298.
144. Ma, Y., Wink, M. (2008). Lobeline, a piperidine alkaloid from Lobelia, can reverse P-gp-dependent multidrug resistance in tumor cells. Phytomedicine 15:754-758.
145. Maher, J. M., Cheng, X., Slitt, A. L., Dieter, M. Z., Klaassen, C. D. (2005). Induction of the multidrug-resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab Dispos 33:956-962.
146. Malingre, M., Richel, D. (2001). Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 19:1160-1166.
147. Manach, C., Williamson, G., Morand, C., Scalbert, A., Remesy, C. (2005). Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81:230S-242S.
148. Marchetti, S., de Vries, N. A., Buckle, T., Bolijn, M. J., van Eijndhoven, M. A., Beijnen, J. H., et al. (2008). Effect of the ATP-binding cassette drug transporters, ABCB1, ABCG2, and ABCC2, on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo phar- macokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple- knockout) and wild-type mice. Mol Cancer Ther 7:2280-2287.
149. McDevitt, C. A., Callaghan, R. (2007). How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther 113:429-441.
150. Ming, X., Thakker, D. R. (2009). Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir, dipivoxil. Biochem Pharmacol 79:455-462.
151. Mitsunaga, Y., Takanaga, H., Matsuo, H., Naito, M., Tsuruo, T. (2000). Effect of bioflavonoids on vincristine transport across blood- brain barrier. Eur J Pharmacol 395:193-201.
152. Mizuno, N., Niwa, T., Yotsumoto, Y., Sugiyama, Y. (2003). Impact of drug-transporter studies on drug discovery and development. Pharmacol Rev 55:425-461.
153. Mizuno, N., Suzuki, M., Kusuhara, H., Suzuki, H., Takeuchi, K., Niwa, T., et al. (2004). Impaired renal excretion of 6-hydroxy-5,7-dime- thyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Drug Metab Dispos 32:898-901.
154. Molnar, J., Gyemant, N., Mucsi, I., Molnar, A., Szabo, M., Kortvelyesi, T., et al. (2004). Modulation of multidrug resistance and apop- tosis of cancer cells by selected carotenoids. In Vivo 18:237-244.
155. Molnar, J., Gyemant, N., Tanaka, M., Hohmann, J., Bergmann-Leitner, E., Molnar, P., et al. (2006). Inhibition of multidrug resistance of cancer cells by
156. Molnar, J., Szabo, D., Pusztai, R., Mucsi, I., Berek, L., Ocsovszki, I., et al. (2000). Membrane-associated antitumor effects of croc- ine-, ginsenoside-, and cannabinoid derivates. Anticancer Res 20:861-867.
157. Moon, Y. J., Morris, M. E. (2007). Pharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin a disposition in rats. Mol Pharm 4:865-872.
158. Morris, M. E., Zhang, S. Z. (2006). Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci 78:2116-2130.
159. Mosley, C. A., Liotta, D. C., Snyder, J. P. (2007). Highly active anticancer curcumin analogues. Adv Exp Med Biol 595:77-103.
160. Nabekura, T., Kamiyama, S., Kitagawa, S. (2005). Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun 327:866-870.
161. Nabekura, T., Yamaki, T., Ueno, K., Kitagawa, S. (2008). Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phy- tochemicals. Cancer Chemother Pharmacol 62:867-873.
162. Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., et al. (2009). Natural compounds for cancer treatment and prevention. Pharmacol Res 59:365-378.
163. Oldham, R. K., Reid, W. K., Barnett, D. (2000). Phase I study of CBT-1 and Taxol in patients with Taxol-resistant cancers. Cancer Biother Radiopharm 15:153-159.
164. Orlowski, S., Valente, D., Garrigos, M., Ezan, E. (1998). Bromocriptine modulates P-glycoprotein function. Biochem Biophys Res Commun 244:481-488.
165. Ozvegy-Laczka, C., Hegedus, T., Varady, G., Ujhelly, O., Schuetz, J. D., Varadi, A., et al. (2004). High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65:1485-1495.
166. Pajeva, I. K., Globisch, C., Wiese, M. (2004). Structure-function relationships of multidrug resistance P-glycoprotein. J Med Chem 47:2523-2533.
167. Pan, Q., Lu, Q., Zhang, K., Hu, X. (2006). Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 58:99-106.
168. Pascaud, C., Garrigos, M. (1998). Multidrug-resistance transporter P-glycoprotein has distinct but interactive binding sites for cytotoxic drugs and reversing agents. Biochemical J 333: 3351-3358.
169. Pires, M. M., Emmert, D., Hrycyna, C. A., Chmielewski, J. (2009). Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol Pharmacol 75:92-100.
170. Pokharel, Y. R., Kim, N. D., Han, H. K., Oh, W. K., Kang, K. W. (2010). Increased ubiquitination of multidrug resistance 1 by ginseno- side Rd. Nutr Cancer 62:252-259.
171. Pratt, S., Shepard, R. L., Kandasamy, R. A., Johnston, P. A., Perry, W., 3rd, and Dantzig, A. H. (2005). The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 4:855-863.
172. Pussard, E., Merzouk, M., Barennes, H. (2007). Increased uptake of quinine into the brain by inhibition of P-glycoprotein. Eur J Pharm Sci 32:123-127.
173. Qiangrong, P., Wang, T., Lu, Q., Hu, X. (2005). Schisandrin B-a novel inhibitor of P-glycoprotein. Biochem Biophys Res Commun 335:406-411.
174. Rabindran, S. K., Ross, D., Doyle, A., Yang, W., Greenberger, L. M. (2000). Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60:47-50. (Pubitemid 30058728)
175. Rees, D. C., Johnson, E., Lewinson, O. (2009). ABC transporters: the power to change. Nat Rev Mol Cell Biol 10:218-227.
176. Reid, G., Wielinga, P., Zelcer, N., van der Heijden, I., Kuil, A., de Haas, M., et al. (2003) The human multidrug resistance protein, MRP4, functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A 100:9244-9249.
177. Rius, M., Nies, A. T., Hummel-Eisenbeiss, J., Jedlitschky, G., Keppler, D. (2003). Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38:374-384.
178. Robey, R. W., Shukla, S., Finley, E. M., Oldham, R. K., Barnett, D., Ambudkar, S. V., et al. (2008). Inhibition of P-glycoprotein (ABCB1)- and multidrug-resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol 75:1302-1312.
179. Ros, J. E., Roskams, T. A., Geuken, M., Havinga, R., Splinter, P. L., Petersen, B. E., et al. (2003). ATP-binding cassette transporter gene expression in rat liver progenitor cells. Gut 52:1060-1067.
180. Rumsby, M., Drew, L., Warr, J. (1998). Protein kinases and multidrug resistance. Cytotechnology 27:203-224.
181. Russo, G. L. (2007). Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol 74:533-544.
182. Santi, C. D., Pietrabissa, A., Spisni, R., Mosca, F., Pacifici, G. M. (2000). Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica 30:609-617.
183. Sarkadi, B., Homolya, L., Szakacs, G., Varadi, A. (2006). Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86:1179-1236.
184. Sarkar, F. H., Li, Y. (2009). Harnessing the fruits of nature for the development of multitargeted cancer therapeutics. Cancer Treat Rev 35:597-607.
185. Sarkar, F. H., Li, Y. W. (2007). Targeting multiple signal pathways by chemopreventive agents for cancer prevention and therapy. Acta Pharmacol Sin 28:1305-1315.
186. Satsu, H., Hiura, Y., Mochizuki, K., Hamada, M., Shimizu, M. (2008). Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals. J Agric Food Chem 56:5366-5373.
187. Scambia, G., Ranelletti, F. O., Panici, P. B., De Vincenzo, R., Bonanno, G., Ferrandina, G., et al. (1994). Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34:459-464.
188. Schwarz, U., Gramatte, T., Krappweis, J., Oertel, R., Kirch, W. (2000). P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 38:161-167.
189. Sesink, A. L. A., Arts, I. C. W., de Boer, V. C. J., Breedveld, P., Schellens, J. H. M., Hollman, P. C. H., et al. (2005). Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol Pharmacol 67:1999-2006.
190. Shaikh, J., Ankola, D. D., Beniwal, V., Singh, D., Kumar, M. N. (2009). Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 37:223-230.
191. Shapiro, A. B., Ling, V. (1997). Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specifities. Eur J Biochem 250:130-137.
192. Shibata, H., Yamakoshi, H., Sato, A., Ohori, H., Kakudo, Y., Kudo, C., et al. (2009). Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo. Cancer Sci 100:956-960.
193. Shimabuku, A. M., Nishimoto, T., Ueda, K., Komano, T. (1992). P-glycoprotein. ATP hydrolysis by the N-terminal nucleotide- binding domain. J Biol Chem 267:4308-4311.
194. Shirasaka, Y., Li, Y., Shibue, Y., Kuraoka, E., Spahn-Langguth, H., Kato, Y., et al. (2009). Concentration-dependent effect of naringin on intestinal absorption of p1-adrenoceptor antagonist talinolol mediated by P-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res 26:560-567.
195. Shitara, Y., Horie, T., Sugiyama, Y. (2006). Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425-446.
196. Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., Srinivas, P. S. (1998). Influence of piperine on the pharmacokinetics of curcu- min in animals and human volunteers. Planta Med 64:353-356.
197. Shukla, S., Wu, C. P., Ambudkar, S. V. (2008). Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Exp Opin Drug Metab Toxicol 4:205-223.
198. Shukla, S., Zaher, H., Hartz, A., Bauer, B., Ware, J. A., Ambudkar, S. V. (2009). Curcumin inhibits the activity of ABCG2/BCRP1, a multi- drug-resistance-linked ABC drug transporter in mice. Pharm Res 26:480-487.
199. Siddiqui, I. A., Adhami, V. M., Bharali, D. J., Hafeez, B. B., Asim, M., Khwaja, S. I., et al. (2009). Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 69:1712-1716.
200. Sikic, B., Fisher, G., Lum, B., Halsey, J., Beketic-Oreskovic, L., Chen, G. (1997). Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40(Suppl):13-19.
201. Slitt, A. L., Cherrington, N. J., Maher, J. M., Klaassen, C. D. (2003). Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites. Drug Metab Dispos 31:1176-1186.
202. Somasundaram, S., Edmund, N. A., Moore, D. T., Small, G. W, Shi, Y. Y., Orlowski, R. Z. (2002). Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 62:3868-3875.
203. Spahn-Langguth, H., Baktir, G., Radschuweit, A., Okyar, A., Terhaag, B., Ader, P., et al. (1998). P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36:16-24.
204. Staud, F., Vackova, Z., Pospechova, K., Pavek, P., Ceckova, M., Libra, A., et al. (2006). Expression and transport activity of breast cancer resistance protein (Bcrp/Abcg2) in dually perfused rat placenta and HRP-1 cell line. J Pharmacol Exp Ther 319:53-62.
205. Sugiyama, Y., Kusuhara, H., Suzuki, H. (1999). Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood- brain and blood-cerebrospinal fluid barriers: importance in the drug delivery to the brain. J Contr Rel 62:179-186.
206. Surh, Y. J. (2003). Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3:768-780.
207. Svehlikova, V., Wang, S., Jakubikova, J., Williamson, G., Mithen, R., Bao, Y. (2004). Interactions between sulforaphane and apigenin in the induction of UGT1A1 and GSTA1 in Caco-2 cells. Carcinogenesis 25:1629-1637.
208. Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., Gottesman, M. M. (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234.
209. Tamai, I., Safa, A. R. (1991). Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug-resistant cells. J Bio Chem 266:16796-16800.
210. Tang, F., Ouyang, H., Yang, J. Z., Borchardt, R. T. (2004). Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK- MDR1 cell monolayers. J Pharm Sci 93:1185-1194.
211. Taur, J. S., Rodriguez-Proteau, R. (2008). Effects of dietary flavonoids on the transport of cimetidine via P-glycoprotein and cationic transporters in Caco-2 and LLC-PK1 cell models. Xenobiotica 38:1536-1550.
212. Tirona, R. G., Bailey, D. G. (2006). Herbal product-drug interactions mediated by induction. Br J Clin Pharmacol 61:677-681.
213. Trompier, D., Baubichon-Cortay, H., Chang, X. B., Maitrejean, M., Barron, D., Riordan, J. R., et al. (2003). Multiple flavonoid-bind- ing sites within multidrug-resistance protein MRP1. Cell Mol Life Sci 60:2164-2177.
214. Troutman, M. D., Thakker, D. R. (2003). Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells. Pharm Res 20:1192-1199.
215. Tsai, T. H., Lee, C. H., Yeh, P. H. (2001). Effect of P-glycoprotein modulators on the pharmacokinetics of camptothecin using microdi- alysis. Br J Pharmacol 134:1245-1252.
216. Tseng, E., Kamath, A., Morris, M. E. (2002). Effect of organic isothiocy- anates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine. Pharm Res 19:1509-1515.
217. Turk, D., Hall, M. D., Chu, B. F., Ludwig, J. A., Fales, H. M., Gottesman, M. M., et al. (2009). Identification of compounds selectively killing multidrug-resistant cancer cells. Cancer Res 69:8293-8301.
218. van Aubel, R. A., Smeets, P. H., Peters, J. G., Bindels, R. J., Russel, F. G. (2002). The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 13:595-603.
219. van de Ven, R., de Jong, M. C., Reurs, A. W., Schoonderwoerd, A. J., Jansen, G., Hooijberg, J. H., et al. (2006). Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. J Immunol 176:5191-5198.
220. van de Ven, R., Oerlemans, R., van der Heijden, J. W., Scheffer, G. L., de Gruijl, T. D., Jansen, G., et al. (2009). ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer. J Leukoc Biol 86:1075-1087.
221. van de Wetering, K., Burkon, A., Feddema, W., Bot, A., de Jonge, H., Somoza, V., et al. (2009). Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/ Mrp3 are involved in the pharmacokinetics of resveratrol. Mol Pharmacol 75:876-885.
222. van Veen, H. W., Venema, K., Bolhuis, H., Oussenko, I., Kok, J., Poolman, B., et al. (1996). Multidrug resistance mediated by a bacterial homolog of the human multidrug transporter, MDR1. Proc Natl Acad Sci U S A 93:10668-10672.
223. van Zanden, J. J., van der Woude, H., Vaessen, J., Usta, M., Wortelboer, H. M., Cnubben, N. H., et al. (2007). The effect of quercetin phase II metabolism on its MRP1 and MRP2 inhibiting potential. Biochem Pharmacol 74:345-351.
224. Versantvoort, C. H., Broxterman, H. J., Lankelma, J., Feller, N., Pinedo, H. M. (1994). Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP- overexpressing human small cell lung cancer cells. Biochem Pharmacol 48:1129-1136.
225. Versantvoort, C. H., Rhodes, T., Twentyman, P. R. (1996). Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds. Br J Cancer 74:1949-1954.
226. Versantvoort, C. H., Schuurhuis, G. J., Pinedo, H. M., Eekman, C. A., Kuiper, C. M., Lankelma, J., et al. (1993). Genistein modulates the decreased drug accumulation in non-P-glycoprotein- mediated multidrug resistant tumour cells. Br J Cancer 68: 939-946.
227. Wacher, V. J., Salphati, L., Benet, L. Z. (2001). Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 46:89-102. (Pubitemid 33653416)
228. Wan, C. K., Zhu, G. Y., Shen, X. L., Chattopadhyay, A., Dey, S., Fong, W. F. (2006). Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells. Biochem Pharmacol 72:824-837.
229. Wang, E. J., Barecki-Roach, M., Johnson, W. W. (2002). Elevation of P-glycoprotein function by a catechin in green tea. Biochem Biophys Res Commun 297:412-418.
230. Wang, E. J., Casciano, C. N., Clement, R. P., Johnson, W. W. (2003). Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res 20:537-544.
231. Wang, X. D., Morris, M. E. (2007). Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab Dispos 35:268-274.
232. Wang, Y. H., Chao, P. D., Hsiu, S. L., Wen, K. C., Hou, Y. C. (2004). Lethal quercetin-digoxin interaction in pigs. Life Sci 74:1191-1197.
233. Washington, C., Duran, G., Man, M., Sikic, B., Blaschke, T. (1998). Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr 19:203-209.
234. Watkins, P. B. (1997). The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27:161-170.
235. Wielinga, P. R., Reid, G., Challa, E. E., van der Heijden, I., van Deemter, L., de Haas, M., et al. (2002). Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 62:1321-1331.
236. Wijnholds, J., Mol, C. A. A. M., van Deemter, L., de Haas, M., Scheffer, G. L., Baas, F., et al. (2000). Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A 97:7476-7481.
237. Williamson, G., Aeberli, I., Miguet, L., Zhang, Z., Sanchez, M. B., Crespy, V., et al. (2007). Interaction of positional isomers of quercetin glucuronides with the transporter ABCC2 (cMOAT, MRP2). Drug Metab Dispos 35:1262-1268.
238. Wu, C. P., Calcagno, A. M., Hladky, S. B., Ambudkar, S. V., Barrand, M. A. (2005a). Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4, and 5 (ABCC1, 4, and 5). FEBS J 272:4725-4740.
239. Wu, C. P., Klokouzas, A., Hladky, S. B., Ambudkar, S. V., Barrand, M. A. (2005b). Interactions of mefloquine with ABC proteins, MRP1 (ABCC1), and MRP4 (ABCC4) that are present in human red cell membranes. Biochem Pharmacol 70:500-510.
240. Yamasaki, Y., Ieiri, I., Kusuhara, H., Sasaki, T., Kimura, M., Tabuchi, H., et al. (2008). Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther 84:95-103.
241. Youdim, K. A., Qaiser, M. Z., Begley, D. J., Rice-Evans, C. A., Abbott, N. J. (2004). Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med 36:592-604.
242. Yoxall, V., Kentish, P., Coldham, N., Kuhnert, N., Sauer, M. J., Ioannides, C. (2005). Modulation of hepatic cytochromes P450 and phase II enzymes by dietary doses of sulforaphane in rats: implications for its chemopreventive activity. Int J Cancer 117: 356-362.
243. Zaher, H., Khan, A. A., Palandra, J., Brayman, T. G., Yu, L., Ware, J. A. (2006). Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 3:55-61.
244. Zelcer, N., Huisman, M. T., Reid, G., Wielinga, P., Breedveld, P., Kuil, A., et al. (2003a). Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Bio Chem 278:23538-23544.
245. Zelcer, N., Reid, G., Wielinga, P., Kuil, A., van der Heijden, I., Schuetz, J. D., et al. (2003b). Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J 371:361-367.
246. Zhang, L., Brett, C. M., Giacomini, K. M. (1998). Role of organic cation transporters in drug absorption and elimination. Annu Rev Pharmacol Toxicol 38:431-460.
247. Zhang, L., Lin, G., Kovacs, B., Jani, M., Krajcsi, P., Zuo, Z. (2007a). Mechanistic study on the intestinal absorption and disposition of baicalein. Eur J Pharm Sci 31:221-231.
248. Zhang, L., Zheng, Y., Chow, M. S. S., Zuo, Z. (2004a). Investigation of intestinal absorption and disposition of green-tea catechins by Caco-2 monolayer model. Int J Pharm 287:1-12.
249. Zhang, L., Zuo, Z., Lin, G. (2007b). Intestinal and hepatic glucuronida- tion of flavonoids. Mol Pharm 4:833-845.
250. Zhang, Q., Wei, D., Liu, J. (2004b). In vivo reversal of doxorubicin resistance by (-)-epigallocatechin gallate in a solid human carcinoma xenograft. Cancer Lett 208:179-186.
251. Zhang, S., Morris, M. E. (2003a). Effect of the flavonoids, biochanin A and silymarin, on the P-glycoprotein-mediated transport of dig- oxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 20:1184-1191.
252. Zhang, S., Morris, M. E. (2003b). Effects of the flavonoids, biochanin A, morin, phloretin, and silymarin, on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304:1258-1267.
253. Zhang, S. Z., Yang, X. N., Morris, M. E. (2004c). Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65:1208-1216.
254. Zhang, W., Han, Y., Lim, S. L., Lim, L. Y. (2009). Dietary regulation of P-gp function and expression. Exp Opin Drug Metab Toxicol 5:789-801.
255. Zhang, W., Lim, L. Y. (2008). Effects of spice constituents on P-glycoprotein-mediated transport and CYP3A4-mediated metabolism in vitro. Drug Metab Dispos 36:1283-1290.
256. Zhang, W., Tan, T. M., Lim, L. Y. (2007c). Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos 35:110-115.
257. Zhang, Y., Talalay, P., Cho, C. G., Posner, G. H. (1992). A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci U S A 89:2399-2403.
258. Zhang, Y. C., Benet, L. Z. (2001). The gut as a barrier to drug absorption-combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159-168.
259. Zhou, L., Naraharisetti, S. B., Wang, H., Unadkat, J. D., Hebert, M. F., Mao, Q. (2008a). The breast cancer resistance protein (Bcrp1/ Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol 73:949-959.
260. Zhou, S., Lim, L. Y., Chowbay, B. (2004). Herbal modulation of P-glycoprotein. Drug Metab Rev 36:57-104.
261. Zhou, S. F., Wang, L. L., Di, Y. M., Xue, C. C., Duan, W., Li, C. G., et al. (2008b). Substrates and inhibitors of human multidrug-resist- ance-associated proteins and the implications in drug development. Curr Med Chem 15:1981-2039.
262. Zhu, X., Sui, M., Fan, W. (2005). In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. Anticancer Res 25:1953-1962.